Literature DB >> 3015405

Phase II trial of epirubicin in hepatoma.

W Shiu, S D Mok, S K O, S Y Tsao, K S Woo, A Li, N Leung, C Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3015405

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

2.  Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.

Authors:  K H Lai; Y T Tsai; S D Lee; W W Ng; H C Teng; T N Tam; G H Lo; H C Lin; H J Lin; J C Wu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4'-epidoxorubicin.

Authors:  W T Leung; W C Shiu; N Leung; M Chan; M Tao; A K Li; C Metreweli
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.